XKRX:083790 (Korea (the Republic of))
Â
Ordinary Shares
â‚©
2880.00
(+13.61%)
Jun 24
Current and historical daily PE Ratio for CrystalGenomics Invites Co Ltd (
XKRX:083790
) from 2006 to Jun 24 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. CrystalGenomics Invites stock (XKRX:083790) PE ratio as of Jun 24 2024 is 0.
More Details
CrystalGenomics Invites Co Ltd (XKRX:083790) PE Ratio (TTM) Chart
CrystalGenomics Invites Co Ltd (XKRX:083790) PE Ratio (TTM) Historical Data
View and export this data going back to 2006. Start your Free Trial
Total 1285
- 1
- 2
- 3
- 4
- 5
- 6
- 15
| CrystalGenomics Invites PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-24 | At Loss | 2024-04-16 | At Loss |
| 2024-06-21 | At Loss | 2024-04-15 | At Loss |
| 2024-06-20 | At Loss | 2024-04-12 | At Loss |
| 2024-06-19 | At Loss | 2024-04-11 | At Loss |
| 2024-06-18 | At Loss | 2024-04-09 | At Loss |
| 2024-06-17 | At Loss | 2024-04-08 | At Loss |
| 2024-06-14 | At Loss | 2024-04-05 | At Loss |
| 2024-06-13 | At Loss | 2024-04-04 | At Loss |
| 2024-06-12 | At Loss | 2024-04-03 | At Loss |
| 2024-06-11 | At Loss | 2024-04-02 | At Loss |
| 2024-06-10 | At Loss | 2024-04-01 | At Loss |
| 2024-06-07 | At Loss | 2024-03-29 | At Loss |
| 2024-06-05 | At Loss | 2024-03-28 | At Loss |
| 2024-06-04 | At Loss | 2024-03-27 | At Loss |
| 2024-06-03 | At Loss | 2024-03-26 | At Loss |
| 2024-05-31 | At Loss | 2024-03-25 | At Loss |
| 2024-05-30 | At Loss | 2024-03-22 | At Loss |
| 2024-05-29 | At Loss | 2024-03-21 | At Loss |
| 2024-05-28 | At Loss | 2024-03-20 | At Loss |
| 2024-05-27 | At Loss | 2024-03-19 | At Loss |
| 2024-05-24 | At Loss | 2024-03-18 | At Loss |
| 2024-05-23 | At Loss | 2024-03-15 | At Loss |
| 2024-05-22 | At Loss | 2024-03-14 | At Loss |
| 2024-05-21 | At Loss | 2024-03-13 | At Loss |
| 2024-05-20 | At Loss | 2024-03-12 | At Loss |
| 2024-05-17 | At Loss | 2024-03-11 | At Loss |
| 2024-05-16 | At Loss | 2024-03-08 | At Loss |
| 2024-05-14 | At Loss | 2024-03-07 | At Loss |
| 2024-05-13 | At Loss | 2024-03-06 | At Loss |
| 2024-05-10 | At Loss | 2024-03-05 | At Loss |
| 2024-05-09 | At Loss | 2024-03-04 | At Loss |
| 2024-05-08 | At Loss | 2024-02-29 | At Loss |
| 2024-05-07 | At Loss | 2024-02-28 | At Loss |
| 2024-05-03 | At Loss | 2024-02-27 | At Loss |
| 2024-05-02 | At Loss | 2024-02-26 | At Loss |
| 2024-04-30 | At Loss | 2024-02-23 | At Loss |
| 2024-04-29 | At Loss | 2024-02-22 | At Loss |
| 2024-04-26 | At Loss | 2024-02-21 | At Loss |
| 2024-04-25 | At Loss | 2024-02-20 | At Loss |
| 2024-04-24 | At Loss | 2024-02-19 | At Loss |
| 2024-04-23 | At Loss | 2024-02-16 | At Loss |
| 2024-04-22 | At Loss | 2024-02-15 | At Loss |
| 2024-04-19 | At Loss | 2024-02-14 | At Loss |
| 2024-04-18 | At Loss | 2024-02-13 | At Loss |
| 2024-04-17 | At Loss | 2024-02-08 | At Loss |
CrystalGenomics Invites Co Ltd (XKRX:083790) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
CrystalGenomics Invites Co Ltd
ISIN : KR7083790006
Share Class Description:
XKRX:083790: Ordinary SharesCompare
Compare
Traded in other countries / regions
083790.Korea IPO Date
2006-01-06Description
CrystalGenomics Invites Co Ltd Formerly CrystalGenomics Inc is one of the leading biopharmaceutical company in Korea. The company is mainly engaged in the research and development and new drug development. It develops innovative new drug development projects such as eradication antibiotics and molecular targeted anticancer drugs. It focuses on arthritic medicines and antibiotics which kill resistant bacteria. It also offers medicines for cancer, obesity, asthma, and diabetes.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers